NASDAQ:TLIS
Talis Biomedical Corporation Stock News
$9.30
+0.0400 (+0.432%)
At Close: May 10, 2024
7-Day Deadline Reminder: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the Firm
06:30pm, Tuesday, 01'st Mar 2022 NewMediaWire
7-Day Deadline Reminder: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the Fir
Talis Biomedical to Announce Fourth Quarter and Full Year Financial Results on March 15, 2022
01:00pm, Tuesday, 01'st Mar 2022 GlobeNewswire Inc.
MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious
NEW YORK, Feb. 28, 2022 /PRNewswire/ -- WHY: New York, N.Y., February 28, 2022. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Talis Biomedical Corporation (NASDAQ: TLIS) pursuant and/or traceable to the registration statement and prospectus…
SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Talis Biomedical Corporation (NASDAQ: TLIS ) investors with significant losses to submit your losses now . A securities class action has been filed concerning defendants'' representations during Talis'' Feb. 2021 initial public offering. Class Period: Feb. 8, 2021 – Jan. 7, 2022 Lead Plaintiff Deadline: Mar. 8, 2022 Visit: www.hbsslaw.com/investor-fraud/TLIS Contact An Attorney Now: [email protected] 844-916-0895 Talis Biomedical Corporation (TLIS) Securities Class Action: Talis touted in its IPO documents that it submitted an application for emergency use authorization ("EUA") to the FDA for its Talis One COVID-19 test in Jan. 2021. The company said it assessed the performance of the Talis One platform comparing nasal specimens with tests conducted in a central lab using the Center for Disease Control and Prevention assay, the test data used to assess the test exactly matched central lab results, and this suggested clinical sensitivity …
SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Talis Biomedical Corporation (NASDAQ: TLIS) investors with significant losses to submit your losses now . A securities class action has been filed concerning defendants’ representations during Talis’ Feb. 2021 initial public offering.
Talis Biomedical Corporation
Talis Biomedical Corporation
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Talis, Talkspace, eHealth, and Oak Street and Encourages Investors to Contact the Firm
02:00am, Thursday, 24'th Feb 2022 GlobeNewswire
NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Talis Biomedical Corporation (NASDAQ: TLIS), Talkspace, Inc. (NASDAQ: TALK), eHealth, Inc. (NASDAQ: EHTH), and Oak Street Health, Inc. (NYSE: OSH). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Talis Biomedical Corporation (NASDAQ: TLIS) pursuant and/or traceable to the registration statement and prospectus (collectively, the Registration Statement) issued in connection with the Companys February 2021 initial public offering (IPO or the Offering), of the important March 8, 2022 lead plaintiff deadline.
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Talis Biomedical Corporation (TLIS) Investors with Losses to Contact Firms Attorneys, Deadline Approaching in Securities Class Action
02:31pm, Tuesday, 22'nd Feb 2022 GlobeNewswire
SAN FRANCISCO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Talis Biomedical Corporation (NASDAQ: TLIS) investors with significant losses to submit your losses now . A securities class action has been filed concerning defendants representations during Talis Feb. 2021 initial public offering.
Investor Notice: March 8th Deadline for Investors who Lost over $100,000 in Talis Biomedical Corporation shares announced by Shareholders Foundation
02:25pm, Tuesday, 22'nd Feb 2022 PR Newswire
SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a deadline is coming up on March 8, 2022, in the lawsuit that was filed for certain investors in (NASDAQ: TLIS) shares. Investors who have losses of over $100,000 from their investment in shares of
NEW YORK, Feb. 21, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Talis Biomedical Corporation (NASDAQ: TLIS) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration
ROSEN, A LEADING LAW FIRM, Encourages Talis Biomedical Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – TLIS
11:54pm, Friday, 18'th Feb 2022 GlobeNewswire
NEW YORK, Feb. 18, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Talis Biomedical Corporation (NASDAQ: TLIS) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s February 2021 initial public offering (“IPO” or the “Offering”), of the important March 8, 2022 lead plaintiff deadline.
Talis Biomedical Corporation Investors: Please contact the Portnoy Law Firm to recover losses
02:00pm, Wednesday, 16'th Feb 2022 GlobeNewswire
Investors can contact the law firm at no cost to learn more about recovering their losses
SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Talis Biomedical Corporation (NASDAQ: TLIS ) investors with significant losses to submit your losses now . A securities class action has been filed concerning defendants'' representations during Talis'' Feb. 2021 initial public offering. Class Period: Feb. 8, 2021 – Jan. 7, 2022 Lead Plaintiff Deadline: Mar. 8, 2022 Visit: www.hbsslaw.com/investor-fraud/TLIS Contact An Attorney Now: [email protected] 844-916-0895 Talis Biomedical Corporation (TLIS) Securities Class Action: Talis touted in its IPO documents that it submitted an application for emergency use authorization ("EUA") to the FDA for its Talis One COVID-19 test in Jan. 2021. The company said it assessed the performance of the Talis One platform comparing nasal specimens with tests conducted in a central lab using the Center for Disease Control and Prevention assay, … Full story available on Benzinga.com
